Akebia Therapeutics came to life four years ago as a two-drug kidney company: Auryxia, a phosphate binder sold into dialysis, and a bet on a then-unapproved anemia drug called Vafseo. This quarter that identity quietly inverts. The company's second fiscal quarter shows Vafseo - the once-daily oral anemia medicine that reached the U.S. market in January 2025 - accelerating as the primary growth engine, while Auryxia, the product that once carried the income statement, cedes ground to generics and pricing pressure. Vafseo net revenue rose to $21.3 million, up a third from the prior quarter and up roughly 60% from the year-ago $13.3 million. Auryxia fell to $25.5 million, down nearly half from $47.2 million a year earlier. Total revenue of $49.1 million was down about a fifth year over year - the arithmetic of the transition playing out in real time.
The quarter answers a question the company has been circling for two years: can Vafseo replace Auryxia quickly enough, and cheaply enough, to matter? The early evidence is genuinely encouraging. More than 10,500 patients were on Vafseo at quarter end, up 41% from the prior quarter, with roughly 1,200 prescribers. And in June, an interim analysis of a large real-world study run with U.S. Renal Care - the VOICE trial, more than 2,100 patients - met its predefined stopping criteria, showing Vafseo dosed three times weekly produced a statistically significant improvement in the composite of all-cause mortality and hospitalization versus erythropoiesis-stimulating agents (win odds 1.16, 95% CI 1.06–1.28), driven by fewer hospitalizations. That is the kind of safety signal management has long argued separates Vafseo from the standard of care.
Yet the stock tells a harsher story. At $0.87, Akebia trades near its 52-week low of $0.82, roughly three-quarters below the $3.40 high of a year ago, and at a market capitalization (~$236 million) that is not far above its $155 million cash balance. The market is not paying for the quarter's Vafseo momentum; it is pricing the two tests that sit ahead - an equity base of just $25 million against roughly $325 million of liabilities, and a senior secured term loan that management must refinance before principal payments begin in January 2027. The commercial thesis is working; the balance-sheet clock is the number that decides whether it gets to compound.